FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> Phase III | Labopharm | Tramadol

Labopharm touts pivotal Tramadol data

Labopharm says that Phase III data backs up its NDA for a once-daily formulation of Tramadol. The pivotal trial compared Tramadol for pain relief against a placebo. The drug was tested in a 12-week trial involving patients with moderate to severe osteoarthritis of the knee.

- read the UPI report


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceBiotech Email Newsletter:

More stories about Phase III   Labopharm   Tramadol